Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

This study has been completed.
Onyx Pharmaceuticals
Information provided by (Responsible Party):
Jennifer Woyach, Ohio State University Comprehensive Cancer Center Identifier:
First received: September 10, 2010
Last updated: May 6, 2016
Last verified: May 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2015
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)